Influenza Clinical Trial
Official title:
Single Blind, Randomized, Actively Controlled Phase 1/2 Study to Compare the Safety and Immunogenicity of a Split Virus, Vero Cell Derived, Seasonal Influenza Vaccine (VCIC) With a Licensed, Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV)
The objective of this study is to assess the safety, tolerability and immunogenicity of a
Split Virus, Vero Cell derived, Seasonal Influenza Vaccine (VCIV) in comparison to a
Licensed Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV) in healthy subjects 18
years of age and older.
Approximately 1000 subjects will be randomly assigned in a 3:1 ratio to receive a single
injection of VCIV or EIV. Subjects will be monitored for 180 days following vaccination for
occurrence of adverse reactions and for antibody response to the vaccine.
Status | Completed |
Enrollment | 1000 |
Est. completion date | September 2007 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Male and female subjects who - Are 18 to 49 years of age (inclusive) on the day of screening (Stratum A) - Are 50 years of age or older on the day of screening (Stratum B) - Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry - Are clinically healthy (in a physical condition such that the physician would have no reservations administering influenza vaccine outside the scope of a clinical study) - Are physically and mentally capable of participating in the study - Agree to keep a daily record of symptoms - If female and capable of bearing children, have a negative urine pregnancy test result within 24 hours of the vaccination on Study Day 0 and agree to employ adequate birth control measures. For the purposes of this study adequate birth control measures incorporate 2 types of the following FDA approved birth control measures through 60 days after vaccination: - Hormonal types of birth control (such as implants, birth control pills, patches or other methods) or an intrauterine device, AND - An additional barrier type of birth control measure (i.e., condoms, diaphragms, cervical caps, etc.) Exclusion Criteria: Subjects who - Have previously been vaccinated against influenza with vaccine formulated for the 2006/2007 influenza season - Have an oral temperature >=37.5°C at the time of vaccination on Day 0 (see note below) - Have Type I diabetes - Have a Body Mass Index >35 - Have hypertension at screening (with or without medication) that is graded as greater than Stage 1 defined as a systolic pressure >159 or diastolic pressure >99 while seated and at rest (measurement may be repeated twice before subject is absolutely excluded) - Have clinically significant abnormal clinical laboratory values at screening - Have clinically significant electrocardiographic abnormalities at screening - Test positive for Human Immunodeficiency Virus(HIV), Hepatitis B Surface Antigen (HbsAg) or Hepatitis C Virus (HCV) - Have a history of cardiovascular disease that required hospitalization - Have a history of immunodeficiency or autoimmune diseases - Have a history of arthritis (joint swelling, tenderness, warmth or erythema) on more than one occasion, not related to trauma (including running) or any episode of non-trauma related arthritis within the previous 6 months - Suffer from active neoplastic disease or have a history of hematologic malignancy - Suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to systemic or high dose inhaled (>800 µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs - Have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis) - Have received any vaccination within 2 weeks prior to vaccination in this study - Have received a blood transfusion or immunoglobulins within 30 days prior to vaccination in this study - Have donated blood or plasma within 30 days prior to vaccination in this study - Have a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to eggs, allergy to components of the test or comparator vaccine, other known contraindications) - Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating - Have a positive urine drug screen (unless the detected drug is currently prescribed by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation) - Were administered an investigational drug within 6 weeks prior to study entry - Are concurrently participating in a clinical study that Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)includes the administration of an investigational product - Are a member of the team conducting this study - Are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator - If female, are pregnant or lactating. NOTE: If all other inclusion/exclusion criteria are met, a subject with a temperature >=37.5°C on Day 0 may be included in the study at a repeat visit provided: 1. They do not have an oral temperature >=37.5°C at the repeat visit, 2. The repeat visit is no more than 5 calendar days after the initial Day 0 visit, 3. The repeat visit is no more than 21 calendar days after all other screening procedures are completed, 4. Subjects are still being recruited at the study site. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Austria | Kinemed | Graz | |
Austria | Universitaetsklinik f. Klinische Pharmakologie, Allgemeines Krankenhaus Wien (University Hospital for Clinical Pharmacology, General Hospital of Vienna) | Vienna | |
Germany | MDS Pharma Services Germany GmbH | Hamburg | |
Germany | Internistische Gemeinschaftspraxis Dr. Regner & Dr. Schmitt (Group practice for internal medicine) | Mainz | |
Germany | Harrison Clinical Research | Munich | |
Poland | Zespol Przychodni Specjalistycznych "DIAB-END-COR" Sp. z o.o. | Krakow | |
Poland | PANTAMED Sp. z o.o. | Olsztyn | |
Poland | Niepubliczny Zaklad Opieki Zdrowotnej, Osrodek Zdrowia w Lipsku | Zamosc |
Lead Sponsor | Collaborator |
---|---|
Nanotherapeutics, Inc. |
Austria, Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the safety and tolerability of Vero cell derived vaccine in comparison to egg-derived vaccine in healthy subjects in two age strata: 18 to 49 years, and 50 years of age and older | |||
Primary | To assess the immunogenicity of Vero cell derived vaccine in comparison to egg-derived vaccine for subjects in two age strata: 18 to 49 years of age and 50 years of age and older |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |